Approval Alert | Pacritinib for Myelofibrosis With Severe Thrombocytopenia

Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.

Ruben Mesa, MD, spoke about which patients stand to benefit the most from the approval of pacritinib in myelofibrosis with severe thrombocytopenia.

Patients with intermediate- or high-risk primary or secondary myelofibrosis with a low platelet count may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.

Ruben Mesa, MD, spoke about the accelerated approval of pacritinib and its importance for the treatment of myelofibrosis with severe thrombocytopenia.